Drug Profile
Montelukast orally-dissolving film - NAL Pharma
Alternative Names: NAL 6336Latest Information Update: 26 May 2022
Price :
$50
*
At a glance
- Originator NAL Pharma
- Class Acetates; Anti-inflammatories; Antiasthmatics; Antidementias; Bronchodilators; Neuroprotectants; Nootropics; Quinolines; Small molecules
- Mechanism of Action Leukotriene D4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Clinical Phase Unknown Allergic rhinitis; Asthma
Most Recent Events
- 26 May 2022 Montelukast orally-dissolving film is still in clinical trials for Allergic rhinitis and Asthma (NAL Pharma pipeline, May 2022)
- 28 Oct 2019 No recent reports of development identified for clinical-Phase-Unknown development in Allergic-rhinitis in Unknown (Sublingual, Film)
- 28 Oct 2019 No recent reports of development identified for clinical-Phase-Unknown development in Asthma in Unknown (Sublingual, Film)